Form 4 for LXRX LEXICON PHARMACEUTICALS, INC.
Accepted 2026-03-03 00:00:00 ET · period of report 2026-02-28 · accession 0001062822-26-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-02-28 | LXRX | Exton Michael | CEO, Dir | F - Tax | $1.47 | -204.8K | 298.4K | -41% | -$301.1K |
| D | 2026-03-03 | 2026-02-28 | LXRX | Exton Michael | CEO, Dir | M - OptEx | — | +503.3K | 503.3K | New | — |
| D | 2026-03-03 | 2026-02-28 | LXRX | Exton Michael | CEO, Dir | M - OptEx | — | -503.3K | 1.01M | -33% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-28 | F | D | 204,831 | $1.47 | 298,432 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-28 | M | A | 503,263 | — | 503,263 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. |
| 3 | Derivative | Restricted Stock Units | 2026-02-28 | M | D | 503,263 | — | 1,006,527 | D | — · — to — | 503,263 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. (F3) Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |